|
 |
AbbokinaseThis page contains recent news articles, when available, and an overview of Abbokinase but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.ImaRx Therapeutics\' commercialization efforts are currently focused on its product Abbokinase? for the treatment of acute massive pulmonary embolism. GuruFocus.com Microbix Sales Grow 22% For Nine Months - Aug 6, 2009 These assets included ImaRx' remaining Urokinase inventory as well as the regulatory file for the product (formerly known as Abbokinase(R), now rebranded as PR Newswire (press release) EkoSonic™ Ultrasound Delivery Reduces Dose of Clot-Busting Drugs ... - Jan 23, 2009 Dr. Katzen went on to say that most of their experience has been based on using urokinase (Abbott: Abbokinase). He said that they have typically reduced the Angioplasty.Org, Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline ... - Dec 10, 2008 ...as Abbokinase(R), now rebranded as Kinlytic(R)), key raw materials for Urokinase manufacture, and the corresponding sales and marketing infrastructure). MarketWatch Microbix Enters The Urokinase Market - Sep 24, 2008 These assets include ImaRx' remaining Urokinase inventory, the regulatory approval to market the product formerly known as Abbokinase(R) (now rebranded as Canada NewsWire (press release), Junior miner surges on gold exploration boost - Sep 24, 2008 Urokinase is an FDA-approved drug formerly marketed by Abbott under the brand name Abbokinase. Microbix said the acquisition will be immediately accretive Stockhouse, Microbix Biosystems Inc. (MBXBF) to Spin off Urokinase Into Newly ... - May 7, 2008 Urokinase is an FDA-approved drug formerly marketed by Abbott under the brand name Abbokinase(R) and is now called Kinlytic. The product has been used to Lifescience-online, Microbix Makes Significant Progress in Implementing Strategic Plan ... - May 14, 2008 These assets would include ImaRx' remaining Urokinase inventory, the NDA (formerly known as Abbokinase(R), now known as Kinlytic(TM)) and the sales and Canada NewsWire (press release), ImaRx Therapeutics Reports Business Update and Financial Results ... - Mar 31, 2008 Formerly marketed as Abbokinase(R), the FDA approved ImaRx's request to market the product under a new trade name, Kinlytic. The Company acquired urokinase PR Newswire (press release), Dutton Associates Announces Investment Opinion: ImaRx Therapeutics ... - Feb 19, 2008 We believe that the shares represent an attractive value at current depressed levels based on current levels of Abbokinase sales, possible development of WELT ONLINE, IMRX: Initiates Coverage @ Speculative Buy w/12-Month Price Target ... - Feb 19, 2008 ImaRx Therapeutics is currently focusing on expanding its commercialization efforts for its FDA approved product, Abbokinase(R) (urokinase), Trading Markets (press release), Microbix Announces First Quarter Results - Feb 13, 2008 ImaRx currently generates about $3 million in sales of Abbokinase per quarter, and this is projected to grow once a long-term supply is established with Canada NewsWire (press release), ImaRx eyes 20 job cuts following its tabling of therapy - Feb 25, 2008 ...said it would halt development of its "microbubble" stroke therapy and instead concentrate efforts boosting sales of an established drug, Abbokinase. Arizona Daily Star, Cubist Pharma Revises Q4 Earnings To Reflect $1.2 Mln Acquisition ... - Feb 13, 2008 ImaRx currently generates about $3 million in sales of Abbokinase per quarter. The company believes that this sales will grow once a long-term supply is RTT News, |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
